Axplora Strategy Teardown: Investing in High-Growth Therapeutics with a Customer-Driven Approach

“We invest to meet the needs of the customer. What’s driving these investments are really the customer partnerships that we’re building to make these happen,” explains Arul Ramadurai, Chief Commercial Officer at Axplora.

Axplora, a global leader in API small molecule and ADC manufacturing, was formed through the merger of Farmabios, Novasep, and PharmaZell. With 2,400 employees across ten API manufacturing sites in Europe, India and the US, the company has recently accelerated its growth strategy with major investments in high-growth areas like GLP-1 peptides and antibody-drug conjugates (ADCs).

In a strategic leadership move to drive this expansion, the company appointed Martin Meeson as its new Chief Executive Officer in April 2024, succeeding Sylke Hassel.

In the latest episode of the PharmaSource podcast we interview Arul Ramadurai about the company strategy.

Full interview

Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma outsourcing.

In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides.

Make sure to subscribe for your regular dose of pharma insight.

• No. of episodes: 160
• Latest episode: 2025-06-22
• Science Life Sciences

Where can you listen?